A rapidly spreading mpox epidemic in the Democratic Republic of Congo (DRC) has led to overcrowded medical facilities, with the Nyiragongo General Referral Hospital in Goma seeing up to 20 new patients daily. The DRC has recorded around 16,000 cases this year, prompting the World Health Organization (WHO) to declare a global health emergency. In response, Danish biotech company Bavarian Nordic announced plans to collaborate with African manufacturers to ramp up vaccine production, aiming to supply up to 2 million doses in 2023. Additionally, Bavarian Nordic has submitted clinical data to the European Medicines Agency to extend the use of its vaccine, Imvanex, to adolescents aged 12-17. This follows interim results showing similar immune responses and safety profiles between adolescents and adults. The company also plans to initiate a clinical trial for children aged 2-12 in the DRC and Uganda later this year.